DNAnexus, Inc., a Mountain View, CA-based provider of cloud-based biomedical data analysis software serving the life sciences community, raised $200m in funding.
The round was led by funds managed by Blackstone Growth (BXG), with participation from existing investors Northpond Ventures, GV, Perceptive Advisors, Innovatus Capital Partners, and Foresite Capital.
The company intends to use the funds to advance its core genomics and multi-omics platform, continue its international growth, and support the integration of new AI and machine learning technologies and tools.
Led by Richard Daly, Chief Executive Officer, DNAnexus is a bioinformatics company that facilitates secure access and utilization of biomedical data while supporting collaboration across internal and external teams. From providing an end-to-end integrated diagnostic R&D and production bioinformatics platform that enables national biobank biomedical initiatives to providing pharmaceutical companies with a multi-omics data science platform for new target drug discovery, DNAnexus enables the healthcare and life sciences industry to leverage biomedical data to accelerate scientific discoveries and deliver better patient care. Customers can rapidly analyze complex genomic, transcriptomic, proteomic, metabolomic, and clinical datasets together on a single, secure, and scalable platform to help reveal insights that can accelerate precision medicine.
Today, DNAnexus has more than 12,000 platform users across 48 countries, and counts seven of the top 10 pharmaceutical and eight of the top 10 diagnostics companies as customers. The platform now stores more than 65 petabytes of data.